A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State
An Open-Label, Randomized, Single Dose Three-Period Partial Crossover Study to Determine the Bioequivalence and Food Effect of a Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.4mg) Compared to Concomitant Dosing of AVODART™ 0.5mg and Flomax 0.4mg Commercial Capsules in Healthy Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78752
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Healthy subjects defined as individuals who are free from clinically significant illness or disease as determined by the investigator based on their medical history, physical examination, laboratory studies, ECGs, and other tests.
- Males who are 18 - 45 years of age, inclusive.
- Weight range 55 - 95 kg (inclusive) and body mass index 19 - 30 kg/m2 (inclusive).
- Willing and able to give written informed consent, willing to participate for the full duration of the study, and able to understand and follow instructions related to study procedures
Exclusion criteria:
- Slow metabolizer for CYP2D6 as determined by screening PGx analysis.
- History of postural hypotension, dizziness, poor hydration, vertigo, vaso-vagal reactions or any other signs and symptoms of orthostasis, which in the opinion of the investigator could be exacerbated by tamsulosin and result in putting the subject at risk of injury.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer, such as St. John's Wort) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
- Chronic hepatitis B and C, as evidence by positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody.
- Positive HIV test at screening.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- History of regular alcohol consumption exceeding 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening. Subjects must be able and willing to abstain from beverages and foods containing alcohol 24 hours prior to and during the dosing day.
- A positive urine drug or alcohol (Breath test or urine) screen result at screening or check-in..
- The subject has received an investigational drug or participated in any other research trial within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication or anytime during the study period.
- Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.
- History or presence of allergy, intolerance, or contraindication to tamsulosin HCl or AVODART or drugs of this class, or a history of drug or other allergy (including true sulfonamide allergy) that, in the opinion of the physician responsible, contraindicates their participation.
- Subjects who have consumed the following foods or drinks within 7 days prior to the first dose of study medication or at any time during the clinical phase of the study: grapefruit juice; red wine; grapefruit or cruciferous vegetables (watercress, broccoli, cabbage, Brussels sprouts).
- QTc ≥ 450 msec at screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fasted state
Subjects will be required to fast overnight.
Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule.
The three treatment periods will be separated by a minimum washout period of 28 days
|
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
|
|
Experimental: Fed state
Subjects will be served high fat breakfast 30 minutes prior to dosing.
Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule.
The three treatment periods will be separated by a minimum washout period of 28 days
|
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma tamsulosin in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve from time zero to infinity (AUC[0-inf]) of plasma tamsulosin in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Concentration maximum (Cmax) of plasma tamsulosin in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma dutasteride in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve (AUC) from time zero to 72 hours (AUC[0-72]) of plasma dutasteride in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Concentration maximum (Cmax) of plasma dutasteride in fed state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma tamsulosin in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve from time zero to infinity (AUC[0-inf]) of plasma tamsulosin in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Concentration maximum (Cmax) of plasma tamsulosin in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve (AUC) from time zero to 24 hours (AUC[0-24]) of plasma dutasteride in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Area under the curve (AUC) from time zero to 72 hours (AUC[0-72]) of plasma dutasteride in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Concentration maximum (Cmax) of plasma dutasteride in fasted state
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Concentration minimum (Cmax) of plasma tamsulosin
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Time to maximum observed plasma drug concentration (tmax) of tamsulosin and dutasteride
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Elimination half-life (t1/2) of tamsulosin and dutasteride
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Negative slope of the terminal phase of tamsulosin and dutasteride
Time Frame: Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
Plasma samples will be collected at indicated time points
|
Pre-dose and post dose at 1,2,3,4,5,6,7,8,10,12,16,24,36,48,72hrs
|
|
Number of subjects with adverse event (AE) and serious adverse event (SAE).
Time Frame: Up to 18 weeks
|
AE is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgement will be categorized as SAE.
|
Up to 18 weeks
|
|
Number of subjects with abnormal clinical laboratory parameters
Time Frame: Up to 18 weeks
|
Blood samples will be collected to analyze aspartate aminotransferase (AST), alkaline Phosphatase (ALP), alanine aminotransferase (ALT), creatinine, blood urea nitrogen, creatine kinase, total bilirubin, direct bilirubin, total protein, albumin, glucose, sodium, potassium, calcium
|
Up to 18 weeks
|
|
Number of subjects with abnormal hematology laboratory parameters
Time Frame: Up to 18 weeks
|
Blood samples will be collected to analyze White Blood Cells (WBC), neutrophils, basophils, eosionophils, lymphocytes, monocytes, Red Blood Cells (RBC) count, RBC indices, Day -1average red blood cell size (MCV), hemoglobin amount per red blood cell (MCH) hemoglobin, hematocrit, and platelet count
|
Up to 18 weeks
|
|
Number of subjects with abnormal urinalysis
Time Frame: Up to 18 weeks
|
Urine samples will be collected to analyze specific gravity, pH, glucose, protein, blood and ketones
|
Up to 18 weeks
|
|
Blood pressure assessment as a measure of safety
Time Frame: Up to 18 weeks
|
Systolic and diastolic blood pressure will be measured in a supine position at pre-dose, Days 2, 3, 4,5,6,7,43 and 85 post-dose
|
Up to 18 weeks
|
|
Measurement of pulse rate as a measure of safety
Time Frame: Up to 18 weeks
|
Pulse rate will be measured in a supine position at pre-dose, Days 2, 3, 4,5,6,7,43 and 85 post-dose
|
Up to 18 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ARI109882
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: ARI109882Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.